A phase 2 clinical investigation to determine the effects of the anti-oxidant bardoxolone on GFR in diabetic chronic kidney disease patients.


Estimated Time to View: 35 minutes
Title: Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Citation: The New England Journal of Medicine, 2011, June 24.
Date Created: 2011
Revisions: None Indicated
Disclaimers: Reata Pharmaceuticals (see page 9)
Resource Type: Video

Recommend to a Colleague/Friend



To view the interactive video, click here
To view this video using an iPad or iPhone, see below

Transparent Peer Review

GD Star Rating

To learn more about our 6-point transparent peer review system, click here

Bardoxolone in Chronic Kidney Disease -- The BEAM Trial, 9.2 out of 10 based on 1 rating


  • Nephrology On-Demand Plus

    Our full-featured iOS app for the iPhone and iPad. NOD + integrates
    1. kidney education,
    2. training, and
    3. recruitment

    into a streamlined and user-friendly interface.


  • Kidney Konnection

    A newsletter that discusses sophisticated topics in Nephrology for physicians in Internal Medicine.
    Click here to access your complimentary subscription
More in CKD, General Nephrology (40 of 212 articles)